Who are Hydroxychloroquine Sulfate Regular dose's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hydroxychloroquine-sulfate-regular-dose.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Hydroxychloroquine Sulfate Regular dose — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hydroxychloroquine Sulfate Regular dose (Hydroxychloroquine Sulfate Regular dose) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Quinoline antimalarial and immunomodulator. Area: Immunology, Rheumatology, Infectious Disease.

marketed Quinoline antimalarial and immunomodulator Lysosomal pH regulation; toll-like receptors (indirect) Immunology, Rheumatology, Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Hydroxychloroquine Sulfate Regular dose (Hydroxychloroquine Sulfate Regular dose) — Government of Punjab, Specialized Healthcare and Medical Education Department. Hydroxychloroquine is a quinoline antimalarial and immunomodulatory agent that inhibits lysosomal function and reduces inflammatory cytokine production.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Hydroxychloroquine Sulfate Regular dose TARGET	Hydroxychloroquine Sulfate Regular dose	Government of Punjab, Specialized Healthcare and Medical Education Department	marketed	Quinoline antimalarial and immunomodulator	Lysosomal pH regulation; toll-like receptors (indirect)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Quinoline antimalarial and immunomodulator class)

Government of Punjab, Specialized Healthcare and Medical Education Department · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Hydroxychloroquine Sulfate Regular dose — Competitive Intelligence Brief. https://druglandscape.com/ci/hydroxychloroquine-sulfate-regular-dose. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing